Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03HVV
|
||||
| Former ID |
DIB006716
|
||||
| Drug Name |
Efaproxyn
|
||||
| Synonyms |
Efaproxiral; RSR13
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Lung cancer [ICD9: 162; ICD10:C33-C34] | Phase 3 | [1] | ||
| Company |
Allos Therapeutics
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H23NO4
|
||||
| Canonical SMILES |
Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1
|
||||
| InChI |
1S/C20H23NO4/c1-13-9-14(2)11-16(10-13)21-18(22)12-15-5-7-17(8-6-15)25-20(3,4)19(23)24/h5-11H,12H2,1-4H3,(H,21,22)(H,23,24)
|
||||
| InChIKey |
BNFRJXLZYUTIII-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Hemoglobin | Target Info | Inhibitor | [2] | |
| KEGG Pathway | African trypanosomiasis | ||||
| Malaria | |||||
| Reactome | Erythrocytes take up carbon dioxide and release oxygen | ||||
| Erythrocytes take up oxygen and release carbon dioxide | |||||
| Scavenging of heme from plasma | |||||
| WikiPathways | Binding and Uptake of Ligands by Scavenger Receptors | ||||
| Uptake of Carbon Dioxide and Release of Oxygen by Erythrocytes | |||||
| Uptake of Oxygen and Release of Carbon Dioxide by Erythrocytes | |||||
| Factors involved in megakaryocyte development and platelet production | |||||
| Folate Metabolism | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00083304) Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer. U.S. National Institutes of Health. | ||||
| REF 2 | Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.